At Emerald Bay, we believe that science should guide every conversation about cannabis and health. One area gaining increasing attention is how cannabinoids may help people living with Parkinson’s disease (PD). Interest is growing, so is the need for clarity. This article explores what current research says about cannabis and PD.
Parkinson’s disease (PD) is a chronic, progressive neurological disorder that primarily affects movement but also influences mood, sleep, and various body functions. PD arises when the areas of the brain that produce dopamine begin to degenerate, leading to reduced levels of dopamine in the brain. This results in abnormal brain function and the formation of protein aggregates called Lewy bodies. PD affects approximately 0.3% of the global population, and its prevalence rises to 1–3% among adults over 60 years old. Its symptoms are grouped into motor and non-motor categories. Motor symptoms include tremors, muscle stiffness (rigidity), slowness of movement (bradykinesia), and balance problems, while non-motor symptoms may involve sleep disturbances, fatigue, anxiety, depression, and cognitive decline.
Standard treatments for PD, such as levodopa, aim to replenish or mimic dopamine, which is the brain chemical that declines in PD. These medications can be highly effective in improving motor symptoms, but their benefits often diminish over time. In fact, long-term use may result in complications like dyskinesia (involuntary movements). Also, conventional therapies fail to address non-motor symptoms adequately, which can significantly affect quality of life. These limitations have led many people with PD to explore complementary approaches like cannabis.
Survey data suggest that cannabis use among people with PD is on the rise. In a U.S. survey of over 1,000 individuals with PD, about 24.5% reported using cannabis within the previous six months. Users were generally younger and more likely to be male. The most common reasons for use were for symptom relief, such as easing anxiety, pain, sleep difficulties, stiffness, and tremor.
Another large real-world study of nearly 1,881 PD patients from the Fox Insight cohort found that about 73% of participants using medical cannabis noticed benefits in pain, anxiety, agitation, and sleep quality.
Overall, these surveys show that many people with PD are self-medicating with cannabis, often without professional guidance. There are reports of meaningful symptom relief, but experiences vary widely depending on the type of product, THC-CBD balance, and individual response, showing the need for more controlled clinical research and supervision.
As a response to this increase in use of cannabis for PD, scientific interest in this area started to grow. Researchers began to study how the body’s own endocannabinoid system interacts with key cannabis compounds like Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). The goal has been to determine whether these cannabis compounds can ease symptoms or slow down the disease progression.
This article reviews current research, highlights what’s promising, what remains uncertain, and what ongoing clinical trials are uncovering. The aim is to give you balanced, evidence-based insights on the use of cannabis in Parkinson’s disease. Let’s get started by talking about the body’s endocannabinoid system.
The Endocannabinoid System (ECS)
The endocannabinoid system (ECS) is a complex network made up of naturally occurring cannabinoids (called endocannabinoids), their receptors, and the chemicals (enzymes) that produce and break them down. This system helps regulate various bodily functions, including movement, mood, and sleep, all of which are affected in Parkinson’s disease (PD).
Research shows that dopamine deficiency, which is the core of PD, causes an alteration in endocannabinoid signaling. As dopamine levels decrease, the brain tries to compensate, and these changes can affect the density and activity of cannabinoid receptors, particularly the CB1 receptors found in the basal ganglia, the brain region that controls movement.
Scientists believe these disruptions in the ECS may contribute to the motor symptoms seen in PD. Also, it was noticed that the activation of CB1 receptors can reduce abnormal firing patterns and potentially reduce dyskinesia in PD, while CB2 activation may suppress neuroinflammation. Because the ECS interacts closely with dopamine pathways, and disruptions in these systems are seen in Parkinson’s disease, researchers began asking whether stimulating or blocking cannabinoid receptors could help restore balance.
Parkinson’s Disease and THC
Pre-clinical research
Laboratory studies became the first step in answering this question, focusing on how cannabinoids like THC and THCV affect brain regions linked to movement and neuroinflammation. These early experiments formed the foundation for understanding how cannabis-based compounds might complement conventional PD treatments.
In several pre-clinical studies, THC, the main psychoactive compound in cannabis, and other CB1 receptor activators were found to help regulate motor circuits in the brain. THC treatment also appeared to reduce inflammation-related cognitive damage. Another compound, tetrahydrocannabivarin (THCV), which has different effects from THC and does not cause a “high,” improves movement problems by acting on cannabis receptors.
Other cannabinoids have shown similar promise in the lab. For instance, β-caryophyllene and cannabigerol (CBG) derivatives such as VCE-003.2 helped reduce oxidative stress and neuroinflammation, protecting dopamine-producing neurons from damage.
Human studies of THC or THC/CBD combinations
Research on THC alone in Parkinson’s disease (PD) is quite limited. Most human studies have tested THC in combination with CBD, rather than as a single compound.
In one small case series involving six participants, researchers gave patients an oral THC:CBD extract at either a low dose (250:28 µg per day) or a higher dose (1000:112 µg per day) for 60 days. The results showed that the higher dose improved sleep quality and hinted at possible cognitive benefits, without causing any significant side effects.
Another clinical study tested a combination of THC and CBD in people living with Parkinson’s disease to see whether it could improve symptoms. In this study, 61 participants took either a capsule containing about 192 mg of CBD and 6 mg of THC per day or a placebo for two weeks. Both groups improved slightly, but the difference was not significant.
Parkinson’s Disease and CBD
Cannabidiol (CBD) is non-intoxicating and interacts only weakly with the body’s main cannabinoid receptors (CB1 and CB2). In pre-clinical studies, CBD has shown antioxidant, anti-inflammatory, and neuroprotective effects, suggesting potential to help protect dopamine-producing neurons and reduce inflammation.
Human studies of CBD
An early open-label study in 2009 explored how CBD might help manage psychosis symptoms in people with PD. Six participants received 150 mg per day for four weeks, and researchers observed significant reductions in hallucinations and delusions without worsening motor function.
A 2014 double-blind clinical trial of 21 participants tested placebo, 75 mg, or 300 mg of CBD per day for six weeks. No significant motor differences were found, but those on 300 mg reported improved quality of life per the PDQ-39 questionnaire.
Other studies—like a phase II dose-escalation trial and a 2022 RCT in Thailand—suggest CBD may improve sleep and emotional control but require careful liver monitoring.
Parkinson’s Disease and Other Cannabinoids
Beyond THC and CBD, cannabinoids like CBG, THCV, and β-caryophyllene show neuroprotective and anti-inflammatory potential in pre-clinical studies. These compounds may modulate ECS enzymes to enhance the body’s natural cannabinoids, helping protect dopamine-producing neurons.
Side Effects, Interactions, and Safety Considerations
Side effects of cannabis-derived products can include dry mouth, dizziness, fatigue, and changes in concentration, especially with high-THC products. CBD can cause digestive issues or mild liver enzyme elevation at high doses. Both THC and CBD are metabolized by the cytochrome P450 system, meaning they can interact with common PD medications like levodopa or antidepressants.
Older adults may experience greater sensitivity to sedation or balance issues, increasing fall risk. Unregulated products may contain contaminants, so sourcing from legal, tested producers is essential. Safer delivery forms include oils or capsules rather than smoking or vaping. Always consult a healthcare professional before use.
Conclusion
Parkinson’s disease remains a challenging condition. Pre-clinical research suggests cannabinoids may offer neuroprotective and anti-inflammatory benefits. Compounds such as THC, CBD, and others have shown encouraging effects in early research, but evidence in humans is still limited due to small study sizes and inconsistent dosing.
Individuals considering cannabis should do so under medical supervision, using only regulated products. As research advances, larger studies will help clarify who may benefit and at what doses. At Emerald Bay, we advocate for responsible, science-driven exploration of cannabis for neurological conditions.